RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with needs in inflammatory diseases and oncology. Utilizing its proprietary drug discovery and development engine, Co. is developing selective small molecules designed to modulate the immune responses underlying these diseases. Co.'s main inflammation drug candidate, RPT193, and its main oncology drug candidate, FLX475, each target C-C motif chemokine receptor 4, a drug target that potentially has applicability in inflammatory diseases and oncology.
RAPT — Key Stats (updated Friday, April 26, 11:31 AM)